The role of probiotics in Helicobacter pylori eradication therapy regimens: current evidence of eff ectiveness
https://doi.org/10.31146/1682-8658-ecg-200-4-160-168
Abstract
One of the most important rules of the modern approach to the treatment of H. pylori infection is to provide eradication therapy to all those infected. Unfortunately, in real clinical practice, doctors and patients often have concerns about the administration of antibiotics, their possible side eff ects and the duration of standard protocols. The increase in antibiotic resistance observed in diff erent countries is also a serious problem, which explains the need to search for alternative therapeutic options for the treatment of Helicobacter infection. In this regard, the search and analysis of the accumulated scientifi c information about the eff ects of including probiotics in the eradication therapy of H. pylori infection is of particular relevance. We have studied the available data on the effi cacy of diff erent probiotic strains in patients infected with H. pylori. Thus, to date, there is strong evidence that the use of probiotics leads to a reduction in the adhesive properties of H. pylori, reduces the degree of bacterial colonization and the severity of infl ammation of the gastric mucosa. Probiotics can be considered a useful adjuvant to standard protocols including antibiotics and proton pump inhibitors, and can be used not only to improve eradication effi cacy, but most importantly to reduce the incidence of gastrointestinal symptoms, which are a frequent cause of reduced adherence and treatment drop-out. We found support for the suggestion that multistrain probiotics are more eff ective than mono-strain probiotics in optimizing eradication therapy in adults and children.
About the Authors
A. G. Kononova
Tver State Medical University
Russian Federation
Russian Federation
Kononova Alla Gennadievna, Candidate of Medical Sciences, Associate Professor of the Department of Polyclinic Therapy and Family Medicine
4, Sovetskaya St., Tver, 170100
S. V. Kolbasnikov
Tver State Medical University
Russian Federation
Russian Federation
Kolbasnikov Sergey Vasilyevich, Doctor of Medical Sciences, Professor, Head, Department of Polyclinic Therapy and Family Medicine, Chief Freelance Specialist in Therapy and Family Medicine of the Ministry of Health of the Tver Region
4, Sovetskaya St., Tver, 170100
S. N. Beldiev
Tver State Medical University
Russian Federation
Russian Federation
Beldiev Sergey Nikolaevich, Candidate of Medical Sciences, Associate Professor, Department of Therapy and Cardiology
4, Sovetskaya St., Tver, 170100
References
1. Sugano K., Tack J., Kuipers E. J., et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–67. doi: 10.1136/gutjnl-2015–309252
2. Mezmale L., Coelho L. G., Bordin D., Leja M. Review: epidemiology of Helicobacter pylori. Helicobacter. 2020;25 Suppl 1: e12734. doi: 10.1111/hel.12734
3. Nyssen О.Р., Perez- Aisa А., Tepes В., et al. Adverse Event Profi le During the Treatment of Helicobacter pylori: A Real- World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). Am J Gastroenterol. 2021;116(6):1220–1229. doi: 10.14309/ajg.0000000000001246
4. Zamani M., Ebrahimtabar F., Zamani V., et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Th er. 2018;47(7):868–876. doi: 10.1111/apt.14561
5. Hooi J. K. Y., Lai W. Y., Ng W. K., et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta- Analysis. Gastroenterology. 2017;153(2):420–429. doi: 10.1053/j.gastro.2017.04.022
6. Lazebnik L.B., Vasiliev Yu.V., Shcherbakov P. L., et al. Helicobacter pylori: prevalence, diagnosis, treatment. Experimental and clinical gastroenterology. 2010;2:3–7 (In Russ.)
7. Kurilovich S.A., Reshetnikov O. V., Krotov S. A., et al. Prevalence of Helicobacter pylori infection in Novosibirsk: 20-year trends. Gastroenterology of St. Petersburg. 2017;1:87–88 (In Russ.)
8. Zhestkova T.V., Butov M. A., Lymar Yu. Yu,, Papkov SV. The prevalence of Helicobacter pylori infection among population of Ryazan region. I. P. Pavlov Russian Medical Biological Herald. 2019;27(1):35–40. (In Russ.) doi: 10.23888/PAVL0VJ201927135–40
9. Bordin D.S., Plavnik R. G., Nevmerzhitskiy V. I., et al. Prevalence of Helicobacter pylori among medical workers in Moscow and Kazan according to the 13C-urease breath test. Almanac of Clinical Medicine. 2018;46 (1):40–49. (In Russ.) doi: 10.18786/2072–0505–2018–46–1–40–49
10. Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol. 1995;19 Suppl 1: S37–43. PMID: 7762738.
11. Alfarouk K.O., Bashir A. H.H., Aljarbou A. N., et al. The possible role of Helicobacter pylori in gastric cancer and its management. Front Oncol. 2019;9:75. doi: 10.3389/fonc.2019.00075
12. Torre L.A., Siegel R. L., Ward E. M., Jemal A. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. doi: 10.1158/1055–9965.EPI-15–0578
13. Nocturne G., Pontarini E., Bombardieri M., Mariette X. Lymphomas complicating primary Sjogren’s syndrome: from autoimmunity to lymphoma. Rheumatology (Oxford). 2019;60(8):3513–21. doi: 10.1093/rheumatology/kez052
14. Maev I.V., Samsonov A. A., Andreev D. N., et al. [Clinical signifi cance of Helicobacter pylori infection]. Klin Med. 2013;91(8):4–12. (In Russ.) PMID: 24437177.
15. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology. Diagnosis, Management. Edited by M. Feldman, L. S. Friedman, L. J. Brandt. 11th ed. 2020.
16. Sugano K., Tack J., Kuipers E. J., et al.; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. doi: 10.1136/gutjnl-2015–309252
17. Ivashkin V. T., Mayev I. V., Lapina T. L., et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55–70. (In Russ.) doi: 10.22416/1382–4376–2018–28–1–55–70
18. Lazebnik L.B., Tkachenko E. I., Abdulganiyeva D. I., et al. VI national guidelines for the diagnosis and treatment ofacid-related and Helicobacter pylori- associated diseases (VI Moscow agreement). Experimental and Clinical Gastroenterology. 2017;(2):3–21. (In Russ.).
19. Ivashkin V.T., Maev I. V., Tsar’kov P.V., et al. Diagnosis and Treatment of Peptic Ulcer in Adults (Clinical Guidelines of the Russian Gastroenterological Association, Russian Society of Colorectal Surgeons and the Russian Endoscopic Society). Russian Journal of Gastro enterology, Hepatology, Coloproctology. 2020;-30(1):49–70. (In Russ.) doi: 10.22416/1382–4376–2020–30–1–49–70
20. Chey W.D., Leontiadis G. I., Howden C. W., Moss S. F. ACG clinical guideline: treatment of helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212–239. doi: 10.1038/ajg.2016.563
21. Wang Z., Graham D. Y., Khan A., et al Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis. Int J Epidemiol. 2018;47(3):966–975. doi: 10.1093/ije/dyy055
22. de Martel C., Forman D., Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am. 2013;42(2):219–40. doi: 10.1016/j.gtc.2013.01.003
23. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J. P., et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30. doi: 10.1136/gutjnl-2016–312288
24. Malfertheiner P., Venerito M., Schulz C. Helicobacter pylori infection: new facts in clinical management. Curr Treat Options Gastroenterol. 2018;16(4):605–15. doi: 10.1007/s11938–018–0209–8
25. Murata M., Sugimoto M., Mizuno H., et al. Clarithromycin versus metronidazole in fi rst-line helicobacter pylori triple eradication therapy based on resistance to antimicrobial agents: meta-analysis. J Clin Med. 2020;9(2). pii: E543. doi: 10.3390/jcm902054314
26. Li B., Lan X., Wang L., et al. Proton-pump inhibitor and amoxicillin based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori:и A meta-analysis. Microb Pathog. 2020;(142):104075. doi: 10.1016/j.micpath.2020.104075
27. Maev I.V., Andreev D. N. Molecular genetic predictors of resistance to anti- Helicobacter pylori therapy. Terapevticheskii Arkhiv. 2017;89(8):5–12. (In Russ.) doi: 10.17116/terarkh20178985–12
28. Myllyluoma E., Veijola L., Ahlroos T., et al Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy – a placebo- controlled, doubleblind randomized pilot study. Aliment Pharmacol Ther. 2005;21(10):1263–72. doi: 10.1111/j.1365–2036.2005.02448.x
29. von Rosenvinge E. C., Song Y., White J. R., et al. Immune status, antibiotic medication and pH are associated with changes in the stomach fl uid microbiota. ISME J. 2013;7(7):1354–66. doi: 10.1038/ismej.2013.33
30. Ye Q., Shao X., Shen R., et al. Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: A systematic review and meta-analysis. Helicobacter. 2020;25(4): e12713. Doi: 10.1111/hel.12713
31. Li B.Z., Th reapleton D. E., Wang J. Y., et al Comparative eff ectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351: h4052. doi: 10.1136/bmj.h4052
32. Quigley E.M.M. Prebiotics and probiotics in digestive health. Clin Gastroenterol Hepatol. 2019;17(2):333–344. doi: 10.1016/j.cgh.2018.09.028
33. Eslami M., Yousefi B., Kokhaei P., et al. Are probiotics useful for therapy of Helicobacter pylori diseases? Comp Immunol Microbiol Infect Dis. 2019;64:99–108. doi: 10.1016/j.cimid.2019.02.010
34. Homan M, Orel R. Are probiot ics useful in Helicobacter pylori eradication? World J Gastroenterol. 2015;21(37):10644–53. doi: 10.3748/wjg.v21.i37.10644
35. Andreev D.N., Maev I. V., Samsonov A. A. The importance of probiotics in optimizing the effi cacy and safety of Helicobacter pylori infection eradication therapy. Meditsinskiy sovet = Medical Council. 2020;(5):9–16. (In Russ.) doi: 10.21518/2079–701X-2020–5–9–16
36. Malfertheiner P., Megraud F., O’Morain C.A., et al.; European Helicobacter Study Group. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut. 2012; 61(5):646–664. doi: 10.1136/gutjnl-2012–302084
37. Shi X., Zhang J., Mo L., et al. Effi cacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019;98(15): e15180. doi: 10.1097/MD.0000000000015180
38. N. Şirvan B., K. Usta M., U. Kizilkan N., Urganci N. Are synbiotics added to the standard therapy to eradicate Helicobacter pylori in children benefi cial? A randomized controlled study. Euroasian J Hepatogastroenterol. 2017;7(1):17–22. doi: 10.5005/jp-journals-10018–1205
39. Mehling H., Busjahn A. Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans. Nutrients. 2013;5(8):3062–73. doi: 10.3390/nu5083062
40. Song H.Y., Zhou L., Liu D. Y., et al. What roles do probiotics play in the eradication of Helicobacter pylori? Current knowledge and ongoing research. Gastroenterol Res Pract. 2018;2018:9379480. doi: 10.1155/2018/9379480
41. Fujimura S., Watanabe A., Kimura K., Kaji M. Probiotic mechanism of Lactobacillus gasseri OLL2716 strain against Helicobacter pylori. J Clin Microbiol. 2012;50(3):1134–6. doi: 10.1128/JCM.06262–11
42. Holtzel A., Ganzle M. G., Nicholson G. J., et al. Th e first low molecular weight antibiotic from lactic acid bacteria: reutericyclin, a new tetramic acid. Angew Chem Int Ed Engl. 2000;39(15):2766–2768. PMID: 10934421.
43. Mehling H., Busjahn A. Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans. Nutrients. 2013;5(8):3062–73. doi: 10.3390/nu5083062
44. Baryshnikova N., Ermolenko E., Svarval A., et al. Enterococcus faecium L-3 in eradication of helicobacter pylori: in-vivo and in-vitro. Int J Clin Med Microbiol Res Artic Open. 2017;1(123):1–4. doi: 10.15344/2456–4028/2017/123
45. Saracino I. M., Pavoni M., Saccomanno L., et al. Antimicrobial effi cacy of fi ve probiotic strains against Helicobacter pylori. Antibiotics. 2020;9(5):1–10. doi: 10.3390/antibiotics9050244
46. Zhang C., Zhang H., Yu L., Cao Y. Helicobacter pylori dwelling on the apical surface of gastrointestinal epithelium damages the mucosal barrier through direct contact. Helicobacter. 2014;19(5):330–42. doi: 10.1111/hel.12138
47. Bordin D.S., Embutnieks Yu.V., Voinovan I. N., Kolbasnikov S. V. The role of probiotics in the treatment of H. pylori infection. Pharmateca. 2017;(6):65–69. (In Russ.)
48. Marcial G., Villena J., Faller G., Hensel A., de Valdez G. F. Exopolysaccharide- producing Streptococcus thermophilus CRL1190 reduces the infl ammatory response caused by Helicobacter pylori. Benef Microbes. 2017;8(3):451–461. doi: 10.3920/BM2016.0186
49. Delgado S., Leite A. M., Ruas- Madiedo P., Mayo B. Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front Microbiol. 2015;5:766. doi: 10.3389/fmicb.2014.00766
50. Wiese M., Eljaszewicz A., Andryszczyk M., et al. Immunomodulatory eff ects of Lactobacillous plantarum and Helicobacter pylori CagA+ on the expression of selected superfi cial molecules on monocyte and lymphocyte and the synthesis of cytokines in whole blood culture. J Physiol Pharmacol. 2012;63(3):217–224. PMID: 22791635.
51. Bordin D.S., Voynovan I. N., Kolbasnikov S. V. Evidence base of lactobacillus reuteri effi cacy in the treatment of diseases associated with Helicobacter pylori. Eksp Klin Gastroenterol. 2016;(8):82–87. (In Russ.) PMID: 29874441.
52. Song H., Zhou L., Liu D., et al. Probiotic effect on Helicobacter pylori attachment and inhibition of infl ammation in human gastric epithelial cells. Exp Ther Med. 2019;18(3):1551–1562. doi: 10.3892/etm.2019.7742
53. Dore M.P., Soro S., Rocchi C., et al. Inclusion ofLactobacillus reuteri in the treatment of Helicobacter pylori in Sardinian patients: A case report series. Medicine (Baltimore). 2016;95(15): e3411. doi: 10.1097/MD.0000000000003411
54. Dore M.P., Bibbo S., Loria M., et al. Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naive or for retreatment of Helicobacter pylori. Two randomized pilot studies. Helicobacter. 2019;24(6): e12659. Doi: 10.1111/hel.12659
55. Tong J.L., Ran Z. H., Shen J., et al. Meta-analysis: the eff ect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Th er. 2007; 25: 155–68. doi: 10.1111/j.1365–2036.2006.03179
56. Zhang M.M., Qian W., Qin Y. Y., et al. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol. 2015; 21 (14): 4345–57. doi: 10.3748/wjg.v21.i14.4345
57. Lu M., Yu S., Deng J., et al. Effi cacy of probiotic supplementation therapy for Helicobacter pylori eradication: a meta-analysis of randomized controlled trials. PLoS One. 2016;11(10): e0163743. doi: 10.1371/journal.pone.0163743
58. Li S., Huang X. L., Sui J. Z., et al. Meta-analysis of randomized controlled trials on the effi cacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr. 2014;173(2):153–161. doi: 10.1007/s00431–013–2220–3
59. Feng J.R., Wang F., Qiu X., et al. Effi cacy and safety of probiotic- supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2017; 73 (10): 1199–208. doi: 10.1007/s00228–017–2291–6
60. Zhou B.G., Chen L. X., Li B., Wan L. Y., Ai Y. W. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019;24(5): e12651. doi: 10.1111/hel.12651
61. Szajewska H., Horvath A., Piwowarczyk A. Metaanalysis: the eff ects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side eff ects during treatment. Aliment Pharmacol Th er. 2010;32(9):1069–79. doi: 10.1111/j.1365–2036.2010.04457
62. Szajewska H., Horvath A., Kotodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Th er. 2015;41(12):1237–45. doi: 10.1111/apt.13214
63. Seddik H., Boutallaka H., Elkoti I., et al. Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial. Eur J Clin Pharmacol. 2019;75(5):639–645. doi: 10.1007/s00228–019–02625–0
64. Chenoll E., Casinos B., Bataller E., et al. Novel probiotic Bifi dobacterium bifi dum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl Environ Microbiol. 2011;77(4):1335–43. doi: 10.1128/AEM.01820–10
65. Islek A., Sayar E., Yilmaz A., Artan R. Bifi dobacterium lactis B94 plus inulin for Treatment of Helicobacter pylori infection in children: does it increase eradication rate and patient compliance? Acta Gastroenterol Belg. 2015;78(3):282–286. PMID: 26448408.
66. Wang, Yh., Huang, Y. Eff ect of Lactobacillus acidophilus and Bifi dobacterium bifi dum supplementation to standard triple therapy on Helicobacter pylori eradication and dynamic changes in intestinal fl ora. World J Microbiol Biotechnol. 2014;30:847–853. doi: 10.1007/s11274–013–1490–2
67. Di Pierro F., Bertuccioli A., Saponara M., Ivaldi L. Impact of a two-bacterial- strain formula, containing Bifidobacterium animalis lactis BB-12 and Enterococcus faecium L3, administered before and after therapy for Helicobacter pylori eradication. Minerva Gastroenterol Dietol. 2020; 66: 117–123. doi: 10.23736/S1121–421X.19.02651–5
68. Lu C., Sang J., He H., et al Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis. Sci Rep. 2016;6:23522. doi: 10.1038/srep23522
69. Kornienko E.A., Minina S. N. Probiotics in the treatment of Helicobacter pylori infection. Medical council. 2015;(14):69–72. (In Russ.)
70. Ji J., Yang H. Using probiotics as supplementation for Helicobacter pylori antibiotic therapy. Int J Mol Sci. 2020;21(3):1136. doi: 10.3390/ijms21031136
71. Handa O., Naito Y., Osawa M., Murao T., Matsumoto H., Umegaki E., Shiotani A. Nutrients and probiotics: current trends in their use to eradicate Helicobacter pylori. J Clin Biochem Nutr. 2020;67(1):26–28. doi: 10.3164/jcbn.20–51
72. Zagari R.M., Frazzoni L., Marasco G., et al. Treatment of Helicobacter pylori infection: a clinical practice update. Minerva Med. 2021;112(2):281–287. doi: 10.23736/S0026–4806.20.06810-X
73. Ermolenko E. I., Molostova A. S., Gladyshev N. S. Eradication therapy of helicobacteriosis with probiotics, problems, and prospects. Experimental and Clinical Gastroenterology. 2021;(9):60–72. (In Russ.) doi: 10.31146/1682–8658-ecg-193–9–60–72
74. Chey W.D., Leontiadis G. I., Howden C. W., Moss S. F. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212–239. doi: 10.1038/ajg.2016.563
75. World Gastroenterology Organisation Global Guidelines. Probiotics and prebiotics. February 2017. Available at: https://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probioticsand-prebiotics-english Accessed: December 22, 2021.
76. Ivashkin V.T., Mayev I. V., Abdulganieva D. I., et al. Practical Recommendations of Scientifi c Society for the Study of Human Microbiome and Russian Gastroenterological Association (RGA) for Probiotics in Treatment and Prevention of Gastroenterological Diseases in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(2):76–89. (In Russ.) doi: 10.22416/1382–4376–2020–30–2–76–89
77. Hemaiswarya S., Kruthiventi A. K., Doble M. Synergism between natural products and antibiotics against infectious diseases. Phytomedicine. 2008;15(8):639–52. doi: 10.1016/j.phymed.2008.06.008
78. Caesar L.K., Cech N. B. Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2. Nat Prod Rep. 2019;36(6):869–888. doi: 10.1039/c9np00011a
79. Brooks B.D., Brooks A. E. Th erapeutic strategies to combat antibiotic resistance. Adv Drug Deliv Rev. 2014 Nov 30;78:14–27. doi: 10.1016/j.addr.2014.10.027
80. Neut C., Mahieux S., Dubreuil L. J. Antibiotic susceptibility of probiotic strains: Is it reasonable to combine probiotics with antibiotics? Med Mal Infect. 2017;47(7):477–483. doi: 10.1016/j.medmal.2017.07.001
Review
For citations:
Kononova A.G., Kolbasnikov S.V., Beldiev S.N. The role of probiotics in Helicobacter pylori eradication therapy regimens: current evidence of eff ectiveness. Experimental and Clinical Gastroenterology. 2022;(4):160-168. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-200-4-160-168
Views:
337
Email this article 